LMWH


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.
Related to LMWH: Fondaparinux

LMWH

Abbreviation for low molecular weight heparin.

heparin

(hep'a-rin) [ hepar + -in]
A parenteral anticoagulant drug with a faster onset than warfarin or its derivatives. It is composed of polysaccharides that inhibit coagulation by forming an antithrombin that prevents conversion of prothrombin to thrombin and by preventing liberation of thromboplastin from platelets. Because heparin is poorly absorbed from the gastrointestinal tract, it is usually administered intravenously or subcutaneously as a sodium or calcium salt.

Uses

Heparin is used as an anticoagulant to prevent and treat thrombosis and embolism. It is an important agent in the management of acute coronary syndromes (e.g., unstable angina pectoris or acute myocardial infarction). Because heparin compounds are too large to cross the placental barrier, they are the preferred anticoagulants in pregnant women. The antagonist for an overdose is protamine sulfate. The most common side effect of heparin is abnormal bleeding.

heparin lock

A device attached to an intravenous catheter to prevent it from clotting. It is used for intermittent administration of fluids or medication. See: heparin lock flush solution; venous access device

low molecular weight heparin

Abbreviation: LMWH
The most bioavailable fraction of heparin. It has a more precise anticoagulant effect than unfractionated heparins and is used to prevent and treat deep venous thrombosis, pulmonary embolism, and acute coronary syndromes.

CAUTION!

It should be used selectively, if at all, in patients with reduced kidney function.

heparitin sulfate

A sulfurated mucopolysaccharide that accumulates in the connective tissue in abnormal amounts in some mucopolysaccharidoses.
See: mucopolysaccharidosis

low molecular weight heparin

Abbreviation: LMWH
The most bioavailable fraction of heparin. It has a more precise anticoagulant effect than unfractionated heparins and is used to prevent and treat deep venous thrombosis, pulmonary embolism, and acute coronary syndromes.

CAUTION!

It should be used selectively, if at all, in patients with reduced kidney function.
See also: heparin
References in periodicals archive ?
paraplegia, pelvic girdle pain with reduced mobility; family history of unprovoked or oestrogen-provoked VTE in first-degree relative; low-risk thrombophilia; multiple pregnancy; in vitro fertilisation-assisted reproductive technology; transient risk factors: dehydration-hyperemesis, current systemic infection, long-distance travel Postnatal assessment Any previous VTE; need for antenatal High risk LMWH; high-risk thrombophilia; low-risk thrombophilia + family history Intermediate/moderate Caesarean section in labour; body mass risk index [greater than or equal to] 40 kg/ [m.sup.2]; readmission or prolonged admission ([greater than or equal to] 3 days) in the puerperium; any surgical procedure in the puerperium other than repair of perineum; medical comorbidities, e.g.
On the other hand, LMWHs, such as enoxaparin have been shown to be as safe and effective as intravenous UFH [20, 21].
Available studies found slow injection decreases pain and bruising size caused by LMWH injection (Palese et al., 2013; Pourghaznein et al., 2014).
* Antepartum and postpartum thromboprophylaxis with LMWH and low-dose aspirin is recommended in women with APS and previous VTE.
He was started on LMWH (enoxaparin) at 1 mg/kg for a planned course of 3 months.
Unfractionated Heparin (UFH) and LMWH are the main types of antithrombotic treatment.
The irreversibility of the patient's clotting assays through exogenous clotting factor transfusion and LMWH antidote (FFP and protamine sulfate accordingly), and the inability to further correct coagulation test abnormalities with a 50:50 mixing test lead to the suspicion of an acquired coagulation factor inhibitor.
Our case report is the first one with LMWH as extended anticoagulant therapy in a patient with IVC duplication and extensive DVT.
By contrast, low molecular weight heparin (LMWH) is a kind of heparin produced by nitrous acid decomposition and purification of low molecular heparin sodium or calcium salts.
During pregnancy, patients are often switched to alternative anticoagulation therapies which include low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH), to avoid teratogenic effects from VKAs.